Chengdu huasun technology group Inc., LTD.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Chengdu Huashen Technology Group Co., Ltd. was founded in 1988 and originated from the first university affiliated pharmaceutical factory of Chengdu University of Traditional Chinese Medicine in China. It was listed on the Shenzhen Stock Exchange through stock reform in 1998, abbreviated as "Huashen Technology", with stock code 000790. After more than 30 years of unremitting struggle, Huashen Technology has grown into a national key high-tech enterprise that integrates modern Chinese medicine and bioengineering. Its subsidiaries include Huashen Technology Group Pharmaceutical Factory, Chengdu University of Traditional Chinese Medicine Huashen Pharmaceutical Co., Ltd., Chengdu Huashen Biotechnology Co., Ltd., Chengdu Huashen Aicao Technology Co., Ltd., Sichuan Huashen Steel Structure Co., Ltd., Sichuan Blue Light Mineral Water Co., Ltd., and more than 1200 employees. Huashen Technology is one of the first batch of technological innovation enterprises in Sichuan Province, a key advantageous enterprise in implementing the cross century development strategy in Sichuan Province, a key advantageous enterprise in Chengdu City, the only Sichuan enterprise to receive the "National High tech Industrialization Ten Year Achievement Award", and one of the two award-winning traditional Chinese medicine enterprises that won the second prize of the National Science and Technology Progress Award in 2020. Relying on key qualifications such as "National Enterprise Technology Center" and "Postdoctoral Research Workstation", Huashen Technology has established an open and mutually beneficial "production, learning, and research" integrated cooperation platform with dozens of domestic and foreign higher education institutions, research institutes, and well-known hospitals, including Sichuan University, Chengdu University of Traditional Chinese Medicine, Sichuan College of Traditional Chinese Medicine, etc., and has successively undertaken national "863" program projects More than 50 national, provincial, and municipal major scientific research projects, including the national level new product trial production plan project, the national enterprise technology center innovation capacity construction project, and the national modern Chinese medicine industry development special project, have won a total of 11 provincial-level and above scientific and technological awards, including the second prize of the National Science and Technology Progress Award. They have won more than 100 international and domestic invention patents, including 4 authorized international invention patents, which have respectively entered Germany, France, Italy, the Netherlands The five countries in the UK have provided strong technological, project support, and innovation empowerment for the development of the group. Huashen Technology's traditional Chinese medicine products cover multiple dosage forms, including capsules, mixtures, tablets, granules, moxibustion agents, and raw materials. It has 26 registered production varieties, including Sanqi Tongshu capsules, Biyuan Shu oral liquid, and Vitality Su oral liquid. 5 varieties are included in the national essential drug catalog, 15 varieties are included in the national medical insurance and work-related injury insurance drugs, and 16 varieties are included in the 2020 edition of the Pharmacopoeia. The diversified variety of product specifications enables the company to maintain a leading market share in the industry. Among them, the core traditional Chinese medicine product Sanqi Tongshu Capsule is a national original Class II new Chinese medicine, a model variety of modernization and internationalization of traditional Chinese medicine, and also the first Chinese medicine extract with independent intellectual property rights to enter the pharmacopoeia of developed Western countries in China. It is also a significant achievement in China's internationalization process of traditional Chinese medicine. Another main product, Biyuanshu Oral Liquid, was identified as a national protected variety of traditional Chinese medicine as early as 1994. In 1995, it won the gold medal at the World Traditional Medicine Conference of the World Health Organization. In 1996, it was listed as a national new drug variety, and in 2008, it obtained a national invention patent. After more than 40 years of clinical application, it has become the first choice and classic treatment drug for rhinitis and sinusitis in the field of otolaryngology. In line with the international advanced technology and process level, Huashen Technology has established a comprehensive production management system and technological innovation management system in the long-term research and development process of new traditional Chinese medicine products and technologies. The company has 7 automated production lines, including pre-treatment and extraction workshops, oral liquid workshops, and capsule workshops. Among them, the notoginseng saponin production line is the first traditional Chinese medicine extraction and purification production line in China that integrates automatic control and near-infrared online monitoring. The production process and quality control technology are at the leading level in China. Huashen Technology's refined management in the manufacturing of traditional Chinese medicine ensures the safety, effectiveness, and quality controllability of drugs. All products have a qualified rate of 100% in internal and external inspections for consecutive years, winning the favor of domestic and foreign customers. Some products are exported to Southeast Asia, Europe and America, and other countries. While the enterprise is steadily developing, Huashen Technology never forgets its original mission, always maintains a high sense of social responsibility, takes the initiative to take responsibility, cares about people's livelihoods, and actively participates in various social public utilities, public welfare undertakings, and glorious undertakings. According to incomplete statistics, since 2006, Huashen Technology has donated over 25.94 million yuan in donations to society. In particular, in the face of the sudden and continuous spread of the COVID-19, Huashen Technology, in combination with its own reality, rushed to aid the epidemic prevention and control, and worked together to overcome the difficulties. Since the COVID-19 prevention and control, the total amount of special donations and materials has reached 10.85 million yuan, including 2 million yuan of donations and 8.85 million yuan of donated materials.Since its establishment, Huashen Technology has adhered to the corporate mission of "Huaxia God Healthy China", unwaveringly promoting the industrialization, internationalization, and independent innovation of traditional Chinese medicine, and committed to promoting the revitalization and development of traditional Chinese medicine in China. Since 2020, as the company has entered a new cycle of strategic development, Huashen Technology has steadfastly inherited traditional Chinese medicine culture, followed the strategic positioning of "seeking long-term value, making high-quality drugs, strengthening the pharmaceutical and health industry", and focused on developing large varieties of traditional Chinese medicine as the strategic focus and driving direction. Through innovative research and development, continuous deepening, and continuous promotion of the deep development of the traditional Chinese medicine industry. At the same time, we are actively exploring the integration and development of high-quality bioengineering such as traditional Chinese medicine, food and medicine maintenance, and health beverage industry ecosystems, as well as pharmaceutical intermediates, characteristic raw materials, and core value product formulations. We are committed to building Huashen Technology into a new commercial force for continuous innovation in China and a leading benchmark for high-level and high-quality development of China's private economy. We are fully committed to drawing and building a grand blueprint for an international pharmaceutical industry group, serving people's livelihoods and benefiting society, Aim globally, with sustainable momentum. |
| Headquarter | Chengdu |
| Establish Date | 1/27/1988 |
| Listed Code | 000790.SZ |
| Listed Date | 3/27/1998 |
| Chairman | Huang Mingliang. |
| CEO | Huang Mingliang. |
| Website | www.huasungrp.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
